Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231633 · ClinicalTrials.gov registry record · NA
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
A NA study of Macular Edema and Central Retinal Vein Occlusion, sponsored by Long Island Vitreoretinal Consultants.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT01231633 is a NA study of Macular Edema and Central Retinal Vein Occlusion that has completed, run by Long Island Vitreoretinal Consultants. The registered enrollment target is 27 participants, below the 178-participant average among 14 other Macular Edema trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT01231633, a NA study of Macular Edema and Central Retinal Vein Occlusion, has completed, sponsored by Long Island Vitreoretinal Consultants.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Conditions Studied
Interventions
- DRUG Avastin
- DRUG Ozurdex
Study Locations (4)
New York
- Long Island Vitreoretinal Consultants - Great Neck
- Long Island Vitreoretinal Consultants - Hauppauge
- Long Island Vitreoretinal Consultants - Riverhead
New Jersey
- Retina Vitreous Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01231633
The ClinicalTrials.gov registry entry for NCT01231633 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 14 other Macular Edema trials with a reported enrollment target (85% lower). The listed sponsor is Long Island Vitreoretinal Consultants, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Avastin is the first listed.
NCT01231633 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01231633 about?
NCT01231633 is a clinical study titled "Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)". The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
What is the current status of trial NCT01231633?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2010-09. Estimated completion is 2014-09.
What conditions does trial NCT01231633 study?
This clinical trial studies the following conditions: Macular Edema, Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT01231633?
The interventions under investigation include: Avastin (DRUG), Ozurdex (DRUG).
Who is sponsoring clinical trial NCT01231633?
This trial is sponsored by Long Island Vitreoretinal Consultants, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01231633 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
COMPLETED · NA
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.